NEW SURGICAL HORIZONS

Cigarette smoking: cancer risks, carcinogens, and mechanisms

Stephen S. Hecht

Received: 26 July 2006 / Accepted: 30 August 2006 / Published online: 10 October 2006 © Springer-Verlag 2006

Abstract

Background Cigarette smoking causes about 30% of all cancer mortality in developed countries. Although smoking is decreasing in developed countries, it is increasing in some developing countries.

Discussion Cigarette smoke contains over 60 well established carcinogens. There are strong links between some of these carcinogens and various types of smoking-induced cancers. Mechanisms by which cigarette smoke carcinogens cause cancer are well established and are discussed here.

Conclusions A great deal is known about cigarette smoke carcinogens and the mechanisms by which they cause cancer. It is hoped that this will provide new insights for the prevention and cure of tobacco-induced cancer.

Keywords Carcinogens · Cigarette smoke · Tobacco · Carcinogenesis mechanisms · DNA adducts

Introduction

Although cigarette smoking has decreased in some countries, there are still about 1,200 million smokers in the world [1, 2]. China alone has approximately 300 million male smokers, about the same as the population of the U.S. [1]. Table 1 summarizes smoking prevalence in the world [2]. Trends in cigarette consumption by development level are shown in Fig. 1 [2]. Globally, about 57% of men and 10% of women smoke tobacco products. Cigarettes are the main type of tobacco product worldwide. About 5.5 trillion cigarettes were

consumed annually in 1990–2000, about 1,000 cigarettes for every person on Earth [1]. Over 15 billion cigarettes are smoked per day [1]. Manufactured cigarettes are available everywhere, but roll-your-own cigarettes are still popular in some areas of the world. Other smoked products include *kreteks*, which are clove-flavored cigarettes popular in Indonesia, and "sticks" which are smoked in Papua New Guinea. *Bidis*, which consist of a small amount of tobacco wrapped in *temburni* leaf and tied with a string, are popular in India and neighboring areas. Cigars and pipes are still used. Water pipes are increasing in popularity.

Cigarette smoking causes well over 1 million cancer deaths annually in the world [2] and about 30% of all cancer deaths in developed countries (Table 2). The corresponding figure for developing countries is 13%. Lung cancer is the dominant malignancy caused by smoking. The total number of cases is estimated to be 1.2 million annually, with about 90% attributed to smoking [3]. Lung cancer was rare at the beginning of the 20th century, but incidence and death rates increased as smoking became more popular. The lung cancer death rate in 1930 for men in the U.S. was only 4.9 per 100,000. By 1990, it had increased to 75.6 per 100,000, parallel to the curve for cigarette smoking prevalence (Fig. 2). The first U.S. Surgeon General's report on the health consequences of cigarette smoking was published in 1964. Subsequently, smoking prevalence began to decrease in the U.S., fairly sharply from 1964 to 1990, and gradually since 1990. There are presently 44.5 million adult smokers in the U.S. about 20.9% of the adult population [4].

Epidemiology of smoking and cancer

In 1950, Wynder and Graham in the U.S. and Doll and Hill in England published the first large-scale studies linking

S. S. Hecht (🖂)

The Cancer Center, University of Minnesota, Box 806 Mayo, 420 Delaware Street SE, Minneapolis, MN, USA e-mail: hecht002@umn.edu

	Prevalance []	percentage of the popula	Number of tobacco users (≥15 years) (millions)			
	Men	Women	Total	Men	Women	Total
WHO region						
African Region	29.4	7.4	18.4	51.967	13.420	65.387
Region of the Americas	32.0	20.9	26.3	94.035	64.072	158.107
Eastern Mediterranean Region	35.3	6.1	21.0	52.543	8.670	61.213
European Region	44.9	18.7	31.2	150.628	68.545	219.173
South-East Asian Region	48.1	5.3	27.3	251.699	26.484	278.183
Western Pacific Region	61.2	5.7	33.8	390.632	35.784	426.416
Levels of development						
Developed	33.9	21.2	27.4	114.783	75.891	190.674
Developing	49.8	7.2	28.9	809.725	114.718	924.443
Transitional	54.1	13.9	32.7	82.837	24.153	106.990
World	57.4	10.3	28.9	1,005.927	217.755	1,223.682

Table 1 Prevalance of cigarette smoking in the world^a


^a From: IARC volume 83, 2004 [2]

smoking and lung cancer [5, 6]. Numerous large international prospective epidemiologic studies and case-control studies involving millions of subjects repeatedly confirmed and extended these findings [3]. The relationship between cigarette smoking and cancer is probably the most researched subject in the history of cancer epidemiology. The 2004 U.S. Surgeon General's Report and Volume 83 of the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans summarize the data [3, 7]. Some of the important conclusions are given here [3].

The strongest determinant of lung cancer in smokers is duration of smoking, and risk also increases with the number of cigarettes smoked [3]. Smoking increases the risk of all histologic types of lung cancer: squamous cell carcinoma, small cell carcinoma, adenocarcinoma (including bronchiolaralveolar carcinoma) and large cell carcinoma. Adenocarcinoma has replaced squamous cell carcinoma as the most common type of lung cancer caused by smoking in the U.S.

and elsewhere. Smoking causes lung cancer in both men and women. Cessation of smoking at any age avoids the further increase in risk of lung cancer caused by continued smoking. However, the risk of ex-smokers for lung cancer remains elevated for years after cessation, compared to the risk of never smokers (Table 3). Cigarette smoking is a major cause of transitional cell carcinomas of the bladder, ureter, and renal pelvis. Similar to lung cancer, risk increases with smoking duration and number of cigarettes smoked, and cessation avoids further increases in risk. Renal cell carcinoma is also associated with smoking [3]. Cigarette smoking is causally associated with cancer of the oral cavity including the lip and tongue in both men and women. Alcohol consumption in combination with smoking greatly increases the risk of oral cancer. Duration of smoking and number of cigarettes smoked are major determinants of risk, and cessation decreases risk [3].

Cigarette smoking increases the risk of sinonasal and nasopharyngeal cancer. It is a cause of oropharyngeal and



consumption in developed and developing countries; From: IARC volume 83, 2004 [2]

Table 2 Estimated percentage of deaths caused by smoking in 1995, all developed countries, by sex, age, and major cause of death groupings^a

Sex	Age	All causes	All cancer	Lung cancer	Upper aerodigestive cancer ^b	Other cancer	Chronic obstructive pulmonary diseases	Other respiratory diseases	Vascular diseases	Other causes
Men	35-69	36	50	94	70	18	82	29	35	35
	70+	21	36	91	59	13	73	11	12	12
	All ages	25	43	92	66	15	75	14	21	18
Women	35-69	13	13	71	34	2	55	16	12	15
	70+	8	13	74	38	2	54	7	5	6
	All ages	9	13	72	36	2	53	7	6	7
Both sexes	35-69	28	35	89	65	10	73	25	28	27
	70+	13	25	86	52	7	65	9	8	8
	All ages	17	30	87	60	8	66	10	13	12


^a From: World Health Organization, 1997 [77]

^bCancers of the mouth, esophagus, pharynx, and larynx.

hypopharyngeal cancer and the risk increases with duration of smoking and daily cigarette consumption and decreases with time since quitting [3]. Cigarette smoking causes cancer of the esophagus, particularly squamous cell cancer. It is also a cause of adenocarcinoma of the esophagus, which has been increasing. The risk for esophageal cancer is related to duration of smoking and number of cigarettes smoked per day and remains elevated after cessation [3]. Laryngeal cancer is caused by cigarette smoking, and the risk increases with duration of smoking and number of cigarettes smoked. Risk is greatly enhanced by alcohol consumption and decreases upon cessation. Similarly, pancreatic cancer and stomach cancer are caused by cigarette smoking and are related to dose [3].

Cigarette smoking is a cause of liver cancer, independent of the effects of hepatitis B and C virus infection and alcohol consumption. Most studies show a relationship to dose and cessation. Similarly, cigarette smoking is a cause of cervical squamous cell carcinoma, controlling for infection with human papilloma virus, a known cause of cervical cancer. Myeloid leukemia in adults is also causally related to cigarette smoking [3]. Cigar and/or pipe smoking are strongly related to cancers of the oral cavity, oropharynx, hypopharynx, larynx, and esophagus, with the risk being similar to that of cigarette smoking. Dose response relationships have been documented. Cigar and/or pipe smoking are causally associated with lung cancer and possibly with cancers of the pancreas, stomach, and urinary bladder [3]. Recent evaluations by the U.S. Surgeon General and the International Agency for Research on Cancer summarize conclusive evidence that secondhand smoke is a cause of lung cancer [3, 8].

Fig. 2 Tobacco use and lung cancer mortality, U.S., 1900-1997. Asterisk (*) Per 100,000 and age-adjusted to 1970 US standard population. Source: Death rates: US mortality public use tapes, 1960-1997, US mortality volumes, 1930-1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 1999. Cigarette consumption: US Department of Agriculture, 1900-1987, 1988, 1989-1997. Figure from: Cancer Prevention & Early Detection Facts & Figures, 2001, American Cancer Society [79]



Years since quitting smoking						
Cohort	0	1-4	5–9	10–14	15–19	20+
British physicians	15.8	16.0	5.9	5.3	2.0	2.0
U.S. veterans	11.3	18.8	7.5	5.0	5.0	2.1
American Cancer Society ^b	13.7	12.0	7.2	1.1	1.1	1.1

 Table 3 Relative risk of developing lung cancer according to years since quitting smoking among males in three cohort studies of smokers^a

From: Blot and Fraumeni, 1996 [78]

^a All risks relative to lifelong nonsmokers

^b Excludes those who smoked less than one pack of cigarettes per day

Carcinogens in cigarette smoke

A carcinogen is any agent, chemical, physical, or viral that causes cancer or increases the incidence of cancer. The chemical carcinogens of cigarette smoke are the causes of cancer. A list of carcinogens in cigarette smoke is presented in Table 4 [2]. All 62 compounds are carcinogenic in laboratory animals, and 15 are carcinogenic in humans. Based on this list, the range of total carcinogen exposure in smokers is approximately 1.4–2.2 mg/cigarette, which can be compared to the current sales-weighted average nicotine delivery of about 0.8 mg/cigarette. However, it should be noted that some of the strongest carcinogens listed in Table 4 (such as polycyclic aromatic hydrocarbons (PAH), N-nitrosamines, and aromatic amines) occur in the lowest amounts while some of the weaker carcinogens (such as acetaldehyde and isoprene) occur in the highest amounts. Thus, simple addition of amounts of carcinogens could be misleading.

PAH are incomplete combustion products that were first identified as carcinogenic constituents of coal tar [9]. They occur as mixtures in tars, soots, broiled foods, automobile engine exhaust, and other materials generated by incomplete combustion [10]. PAH are usually locally acting carcinogens, and some, such as benzo[*a*]pyrene (BaP), have powerful carcinogenic activity. PAH carcinogenicity has typically been evaluated by application to mouse skin, but they also induce tumors of the lung, trachea, and mammary gland depending on the route of administration and animal model used [11]. BaP is considered carcinogenic to humans by IARC [12].

Heterocyclic compounds include nitrogen-containing analogues of PAH and simpler compounds such as furan, a liver carcinogen. *N*-Nitrosamines are a large class of carcinogens with demonstrated activity in at least 30 animal species [13]. *N*-Nitrosamines are potent systemic carcinogens that affect different tissues depending on their structures. Two of the most important *N*-nitrosamines in cigarette smoke are the tobacco-specific *N*-nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and *N'*-nitrosonornicotine (NNN) [14]. NNK and NNN are found only in tobacco products. NNK causes lung tumors in all species tested and has particularly high activity in the rat. NNK can also induce tumors of the pancreas, nasal cavity, and liver. NNN produces esophageal and nasal tumors in rats and respiratory tract tumors in mice and hamsters [15]. NNK and NNN are considered as carcinogenic to humans by IARC [16].

Aromatic amines are combustion products and include the well-known human bladder carcinogens 2-naphthylamine and 4-aminobiphenyl, first characterized as human carcinogens due to industrial exposures in the dye industry [17]. Heterocyclic aromatic amines are also combustion products and are best known for their occurrence in broiled foods [18]. Aldehydes such as formaldehyde and acetaldehyde occur widely in the human environment and are also endogenous metabolites found in human blood [19, 20]. The phenolic compounds catechol and caffeic acid are common dietary constituents. Relatively high doses of catechol, administered in the diet, cause glandular stomach tumors. Catechol can also act as a co-carcinogen [20]. Dietary caffeic acid caused renal cell tumors in female mice [21]. The volatile hydrocarbons include 1,3-butadiene, a powerful multi-organ carcinogen in the mouse, with weaker activity in the rat, and benzene, a known human leukemogen [22, 23]. 1,3-Butadiene and benzene are arguably the two most prevalent strong carcinogens in cigarette smoke.

Among the other carcinogenic organic compounds in cigarette smoke are the human carcinogens vinyl chloride, in quite low amounts, and ethylene oxide, in substantial quantities [24, 25]. Ethylene oxide is associated with malignancies of the lymphatic and hematopoietic system in both humans and experimental animals [25]. Diverse metals and the radionuclide polonium-210 are also present in cigarette smoke. Cigarette smoke also contains oxidants such as nitric oxide (up to 600 µg per cigarette) and related species [26]. Free radicals have been detected by electron spin resonance and spin trapping [26]. The major free radical species are postulated to be a quinone-hydroquinone complex. In addition, several studies demonstrate the presence in cigarette smoke of an as yet uncharacterized ethylating agent, which ethylates both DNA and hemoglobin [27, 28]. In summary, there are diverse carcinogens in

Table 4 Carcinogens in cigarette smoke

	Carcinogen	Amount in mainstream cigarette smoke	<i>IARC Monographs</i> evaluation of carcinogenicity			Monograph volume, year	
Dend/planthaccne 20 70 ng Sufficient 2A 22, 1983a, 57, 1987 Berazd/Humorahnen 6-21 ng Sufficient 2B 32, 1983a, 57, 1987 Berazd/Humorahnen 6-12 ng Sufficient 2B 32, 1983a, 57, 1987 Berazd/Hymorahnen 6, 12 ng Sufficient 2B 32, 1983a, 57, 1987 Berazd/Hymorahnen 6, 12 ng Sufficient 2B 32, 1983a, 57, 1987 Diberazd, Pyrene 17, 32 ng Sufficient 2B 32, 1983a, 57, 1987 Diberazd, Pyrene 7, 32 ng Sufficient 2B 32, 1983a, 57, 1987 Diberazd, Pyrene N-0 o ng Sufficient 2B 32, 1983a, 57, 1987 Furan 20-40 µg Sufficient 2B 32, 1983a, 57, 1987 Diberazd, Bjeridine ND-0 ng Sufficient 2B 32, 1983a, 57, 1987 Diberazd, Bjeridine ND-0 ng Sufficient 2B 32, 1983a, 57, 1987 Nitrosochydrawale ND-0 ng Sufficient 2B 32, 1983a, 57, 1987 Nitrosochydrawale ND-0 n			In animals	In humans	IARC Group		
Berazi/filonanthene 4.22 ng' Sufficient 2B 32, 1983; 57, 1987 Berazi/filonanthene 6-12 ng Sufficient 2B 32, 1983; 57, 1987 Berazi/filonanthene 6-12 ng Sufficient 2B 32, 1983; 57, 1987 Berazi/filonanthene 4 ng Sufficient 2B 32, 1983; 57, 1987 92, 20 Dibenzo(a/lpyrene 1.7.3.2 ng Sufficient 2B 32, 1983; 57, 1987 92, 1983; 57, 1987 Dibenzo(a/lpyrene 1.7.3.2 ng Sufficient 2B 32, 1983; 57, 1987 Dibenzo(a/lpyrene 4-20 ng Sufficient 2B 32, 1983; 57, 1987 Dibenzo(a/lpyrene ND-0.6 ng Sufficient 2B 32, 1983; 57, 1987 Dibenzo(a/lparinance ND-0.0 ng Sufficient 2B 32, 1983; 57, 1987 Dibenzo/lparinance ND-0.7 ng Sufficient 2B 32, 1983; 57, 1987 Nitrosonthynamine ND-10 ng Sufficient 2B 7, 1978; 57, 1987 Nitrosonthynamine ND-13 ng Sufficient 2B 7, 1978; 57, 1987 <t< td=""><td>Polycyclic aromatic hydrocarb</td><td>ons (PAH)</td><td></td><td></td><td></td><td></td></t<>	Polycyclic aromatic hydrocarb	ons (PAH)					
Berazyl/Illuoranthene 6-21 ng Sufficient 2B 23, 1983a; 57, 1987 Berazyl/Illuoranthene 6-12 ng Sufficient Limited 1 32, 1983a; 57, 1987, 192, 20 Berazyl/Illuoranthene 4 ng Sufficient 2A 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Fuerocyclic componds - - 2B 32, 1983a; 57, 1987 Dibenz/a/Jprine ND-0.1 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprine ND-0.1 ng Sufficient 2B 32, 1983a; 57, 1987 Nitrosodimethylamine ND-1.1 ng Sufficient 2B 32, 1983a; 57, 1987 Nitrosodimethylamine ND-25 ng Sufficient 2B 71, 1978; 57, 1987 Nitro	Benz[a]anthracene	20–70 ng	Sufficient		2A	32, 1983a; S7, 1987	
Berazyl/Illuoranthene 6-21 ng Sufficient 2B 23, 1983a; 57, 1987 Berazyl/Illuoranthene 6-12 ng Sufficient Limited 1 32, 1983a; 57, 1987, 192, 20 Berazyl/Illuoranthene 4 ng Sufficient 2A 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprivene 1.7-3.2 ng Sufficient 2B 32, 1983a; 57, 1987 Fuerocyclic componds - - 2B 32, 1983a; 57, 1987 Dibenz/a/Jprine ND-0.1 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenz/a/Jprine ND-0.1 ng Sufficient 2B 32, 1983a; 57, 1987 Nitrosodimethylamine ND-1.1 ng Sufficient 2B 32, 1983a; 57, 1987 Nitrosodimethylamine ND-25 ng Sufficient 2B 71, 1978; 57, 1987 Nitro		4–22 ng	Sufficient		2B	32, 1983a; S7, 1987	
Berazo[a]pursane 6-12 ng Sufficient 2B 23, 1983a; S7, 1987 Berazo[a]pursane 8.5-17.6 ng Sufficient 2A 23, 1983a; S7, 1987 22, 20 Dibenz(a/a)pursane 4 ng Sufficient 2B 22, 1983a; S7, 1987 20, 200 Dibenz(a/a)pursane 4 ng Sufficient 2B 22, 1983a; S7, 1987 Dibenz(a/a)pursane 4-20 ng Sufficient 2B 22, 1983a; S7, 1987 Sufficient 2B 52, 1983a; S7, 1987 54 54, 1985b Dibenz[a/a)facidine ND-0.6 ng Sufficient 2B 63, 1995b Dibenz[a/a)facidine ND-0.7 ng Sufficient 2B 22, 1983a; S7, 1987 Dibenz[a/a)facidine ND-0.7 ng Sufficient 2B 32, 1983a; S7, 1987 Nitrosochimethylamine ND-1.7 ng Sufficient 2B 32, 1983a; S7, 1987 Nitrosochimethylamine ND-1.7 ng Sufficient 2B 32, 1983a; S7, 1987 Nitrosochimethylamine ND-1.7 ng Sufficient 2A 17, 1578; S7, 1987		-	Sufficient		2B		
Beresolphysene 8.4–17.6 ng Sufficient 1 32, 1983a, 57, 1987, 52, 20 Dibenzo(a/lpyrene 1.7–3.2 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenzo(a/lpyrene Present Sufficient 2B 32, 1983a, 57, 1987 Dibenzo(a/lpyrene Present Sufficient 2B 32, 1983a, 57, 1987 Inden(1,2,3–47, dpyrene 4.20 ng Sufficient 2B 32, 1983a, 57, 1987 Furan D-0.6 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenzo/a/lportidine ND-0.1 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenzo/a/lportidine ND-0.7 ng Sufficient 2B 32, 1983a, 57, 1987 A/Nitrosodienthylamine ND-13 ng Sufficient 2B 7, 1978, 57, 1987 A/Nitrosodienthylamine ND-25 ng Sufficient 2B 7, 1978, 57, 1987 A/Nitrosodienthylamine ND-36 ng Sufficient 2B 7, 1978, 57, 1987 A/Nitrosodienthylamine ND-26 ng Sufficient 2B 7, 1978, 57, 1987, 69, 200 A/Nitrosodien		6–12 ng	Sufficient				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		C	Sufficient	Limited			
Dibersola, Ipyrene 1.7-3.2 ng Sufficient 2B 32, 1983; S7, 1987 Dibersola, elpyrene Present Sufficient 2B 32, 1983; S7, 1987 S-Methylchrysene ND-0.6 ng Sufficient 2B 32, 1983; S7, 1987 Furn 20-04 ug Sufficient 2B 32, 1983; S7, 1987 Dibenz(a,l)arridine ND-0.1 ng Sufficient 2B 32, 1983; S7, 1987 Dibenz(a,l)arridine ND-0.1 ng Sufficient 2B 32, 1983; S7, 1987 Dibenz(a,l)arridine ND-0.1 ng Sufficient 2B 32, 1983; S7, 1987 Norsondimethylamine ND-1.1 ng Sufficient 2A 17, 1978; S7, 1987 N-Nitrosodimethylamine ND-2.5 ng Sufficient 2A 17, 1978; S7, 1987 N-Nitrosodienkolonamine ND-36 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosodienkolonamine ND-36 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosodienkolonamine ND-36 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosodienkolonamine <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td>		-					
Diberog($a, b)$ prene Present Sufficient 2B 32, 1983a, S7, 1987 Inden($l, 2, l$ -afglyrene 4-20 ng Sufficient 2B 32, 1983a, S7, 1987 S-Methylchrysene ND-0.6 ng Sufficient 2B 32, 1983a, S7, 1987 Paran 20-40 μ g Sufficient 2B 63, 1995b Dibeng(a, b)acridine ND-0.1 ng Sufficient 2B 32, 1983a, S7, 1987 Dibeng(a, b)acridine ND-0.7 ng Sufficient 2B 32, 1983a, S7, 1987 N-Nitrosochimethylamine ND-1.7 ng Sufficient 2B 32, 1983a, S7, 1987 N-Nitrosochimethylamine ND-1.7 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosochimethylamine ND-13 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosochirethylamine ND-25 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosochirethanolamine ND-3 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosochirethanolamine ND-3 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitr							
		-					
5-Methylchrysene ND-0.6 ng Sufficient 2B 32, 1983a, 57, 1987 Heterocyclic compounds							
Heterocyclic compounds Valuation Valuation Valuation Valuation Furan 20–40 µg Sufficient 2B 63, 1995h Dibenz(a/Jacridine ND-0.1 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenz(a/Jacridine ND-0.7 ng Sufficient 2B 32, 1983a, 57, 1987 Benzo(b/Jitran Present Sufficient 2B 32, 1983a, 57, 1987 A-Nitrosodimethylamine 0.1–180 ng Sufficient 2A 17, 1978; 57, 1987 A-Nitrosodimethylamine ND-25 ng Sufficient 2B 17, 1978; 57, 1987 A-Nitrosodiethylamine ND-25 ng Sufficient 2B 17, 1978; 57, 1987 A-Nitrosopiperidine ND-9 ng Sufficient 2B 17, 1978; 57, 1987 A-Nitrosopiperidine ND-36 ng Sufficient 2B 17, 1978; 57, 1987 A-Nitrosopiperidine ND-36 ng Sufficient 2B 17, 1978; 57, 1987 A-Mitrosopiperidine ND-36 ng Sufficient 2B 17, 1978; 57, 1987 A-Mitrosopiperidine ND-30 ng Sufficient 2B 17, 1978; 57, 1987 A-		C					
Funan 20-40 µg Sufficient 2B 63, 1995b Dibenz(a,b]acridine ND-0.1 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenz(a,b]acridine ND-0.7 ng Sufficient 2B 32, 1983a, 57, 1987 Dibenz(a,b]acridine ND-0.7 ng Sufficient 2B 32, 1983a, 57, 1987 ANitrosodinethylamine 0. 1–180 ng Sufficient 2B 47, 1978; 57, 1987 N-Nitrosodinylamine ND-13 ng Sufficient 2A 17, 1978; 57, 1987 N-Nitrosodinylmethylamine ND-25 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodirbylamine ND-3 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodirbylamine ND-3 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodirbylamine ND-3 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodirbylamine ND-4 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodirbylamine ND-4 ng Sufficient Limited 1 37, 1987; 77, 2000 2.6-Dimethyl		11D 0.0 Hg	Sumerent		20	52, 1965 u , 57, 1967	
Dibenz[a,h]acridine ND-0.1 ng Sufficient 2B 32, 1983a; S7, 1987 Dibenz($c_z)$ [acridance ND-0.0 ng Sufficient 2B 32, 1983a; S7, 1987 Dibenz($c_z)$ [acridance ND-0.7 ng Sufficient 2B 32, 1983a; S7, 1987 Netrosodimethylamine Present Sufficient 2B 63, 1995b N-Nitrosodimethylamine N. 1-180 ng Sufficient 2A 17, 1978; S7, 1987 M-Nitrosoditylmethylamine ND-25 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophyrolidine 1.5-110 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophyrolidine ND-3 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosophyrolidine ND-4 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosophyrolidine 154-196 ng Sufficient Limited 1 37, 1985; S7, 1987, 2000 (3-pyridyl)-1-butance Z-robudine 30-200 ng Sufficient Limited 1 37, 1987; 77, 2000 2.6-Dimethylamine 1-22 ng Sufficient <t< td=""><td></td><td>20-40 μα</td><td>Sufficient</td><td></td><td>2B</td><td>63 1995h</td></t<>		20-40 μα	Sufficient		2B	63 1995h	
Dibenz[a,f]scridine ND-10 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenzo(z,g)carbazole ND-0.7 ng Sufficient 2B 32, 1983a; 57, 1987 Dibenzo(z,g)carbazole ND-0.7 ng Sufficient 2B 32, 1983a; 57, 1987 N-Nitrosodimethylamine 0. 1–180 ng Sufficient 2A 17, 1978; 57, 1987 N-Nitrosodithylamine ND-13 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosodithylamine ND-25 ng Sufficient 2B 17, 1978; 57, 1987 N-Nitrosopiperidine ND-36 ng Sufficient 2B 17, 1978; 57, 1987, 92, 000 N-Nitrosofiethanolamine ND-36 ng Sufficient Limited 1 37, 1985; 57, 1987, 92, 000 N-Nitrosonomicotine 154–196 ng Sufficient Limited 1 37, 1985; 57, 1987, 92, 000 A'Moritosodithylamine 154–196 ng Sufficient Limited 2A 57, 1987, 77, 2000 2,6-Dimethylanine 14–20 ng Sufficient Sufficient 2B 57, 1987 2,7-Dudidine 30–200 ng						,	
Dihemological carbon of the second stress of the second strese stress of the second stress of the second stress		_					
Benzol/firm Present Sufficient 2B 63, 1995b N-Nitrosodimethylamine 0. 1–180 ng Sufficient 2A 17, 1978; S7, 1987 M-Nitrosodimethylamine ND-13 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophylmethylamine ND-25 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophyrolidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophyrolidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosophyrolidine ND-36 ng Sufficient 2B 17, 1978; S7, 1987, 77, 2000 M-Nitrosophyrolidine ND-36 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 G.a-pyridyl-1-butanone A Caronatic amines Z Z Z Z Z Sufficient Limited 1 4, 1974; S7, 1987 C-formethylamine 1–22 ng Sufficient Sufficient 2B 40, 1986b; S7, 1987 C-fo-imethylamine 1–22 ng Sufficient 2B 40, 1986b; S7, 1987 <		•					
M-Nitrosamines Variance M-Nitrosochinethylamine 0. 1–180 ng Sufficient 2A 17, 1978; S7, 1987 M-Nitrosochivplentylamine ND-25 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosochivplentylamine ND-25 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosopipredine 1.5–110 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosopipredine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 M-Nitrosonicotine 154–196 ng Sufficient 2B 17, 1978; S7, 1987; 89, 200 A'-Nitrosonicotine 154–196 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 (3-pyridyl)-1-butanone - - 2-101uidine 30–200 ng Sufficient Limited 1 37, 1987; 77, 2000 2-6-Dimethylaniline 4–50 ng Sufficient Sufficient 2B 57, 1987 4-Aminobiphenyl 2–5 ng Sufficient Sufficient 1 4, 1974; S7, 1987 A-Amicobiphenyl 2–5 ng Sufficient 2B 40, 1986b; S7, 1987 MeA- ∞ -C 2–30 ng Suf		e					
N-Nitrosodimethylamine 0. 1–180 ng Sufficient 2A 17, 1978; S7, 1987 M-Nitrosotiyhlmethylamine ND-13 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosotiethylamine ND-25 ng Sufficient 2A 17, 1978; S7, 1987 N-Nitrosopiperidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopiperidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopiperidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopiperidine ND-36 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopiperidine ND-36 ng Sufficient Limited 1 37, 1985; S7, 1987 N-Nitrosoprinyl)-1-butanoe 10–133 ng Sufficient Limited 1 37, 1985; S7, 1987 A-croact anomatic amines - - 2-Toluidine 30–200 ng Sufficient Sufficient 1 1, 1972; S7, 1987 A-cact anomatic amines - - - 1, 1972; S7, 1987 Mea-a-C 25-260 ng Sufficient Sufficient 2B 40, 1986b;		Flesent	Sumclent		20	05, 19950	
N·Nitrosoethylmethylamine ND-13 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopyrolidine ND-25 ng Sufficient 2A 17, 1978; S7, 1987 N-Nitrosopyrolidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopyrolidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosononicotine ND-36 ng Sufficient 2B 17, 1978; S7, 1987; 89, 200 M-Nitrosononicotine 154–196 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 A-Mornatic amines -		0 1 180 mg	Sufficient		2 4	17 1079, 57 1097	
N-Nitrosodiethylamine ND-25 ng Sufficient 2A 17, 1978; S7, 1987 N-Nitrosopierdine 1.5-110 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopierdine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopierdine ND-36 ng Sufficient 2B 17, 1978; S7, 1987, 39, 200 M-Nitrosomino:1ne 154-196 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 4-(Methylnitrosamino)-1- 110-133 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 2-hynithylnih 110-133 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 2-holinethylaniline 4-50 ng Sufficient Sufficient 2B 57, 1987; 77, 2000 2-holinthylaniline 1-22 ng Sufficient Sufficient 1 1, 1974; S7, 1987 4-Aminobiphenyl 2-5 ng Sufficient Sufficient 1 1, 1974; S7, 1987 Heterocyclic aromatic amines - 2-37 ng Sufficient 2B 40, 1986b; S7, 1987		C					
N-Nitrosopyrolidine 1.5-110 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosopieridine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosonichanolamine ND-3 ong Sufficient 2B 17, 1978; 77, 2000 N-Nitrosonichanolamine 154-196 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 4-(Methylnitrosamino)-1 110-133 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 (3-pyridyl)-1-butanone - <t< td=""><td></td><td>-</td><td></td><td></td><td></td><td></td></t<>		-					
N-Nitrosopiperidine ND-9 ng Sufficient 2B 17, 1978; S7, 1987 N-Nitrosodiethanolamine ND-36 ng Sufficient Limited 1 37, 1985; 87, 2000 N-Nitrosonomicotine 14-196 ng Sufficient Limited 1 37, 1985; 87, 2000 N-Nitrosonomicotine 14-196 ng Sufficient Limited 1 37, 1985; 87, 2000 (3-pyridyl)-1-butanone -	5	e					
N-Nitrosodiethanolamine ND-36 ng Sufficient 2B 17, 1978; 77, 2000 M'-Nitrosonomicotine 154–196 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 4-(Methylnitrosamino)-1- 110–133 ng Sufficient Limited 1 37, 1985; S7, 1987; 89, 200 G-pyridylyl-1-butanone - - - 1 37, 1985; S7, 1987; 89, 200 Aromatic amines - - - N - 1 37, 1985; S7, 1987; 89, 200 2-Folludine 30–200 ng Sufficient Limited 2A S7, 1987; 77, 2000 2-Folludine 4-50 ng Sufficient 2B 57, 1987; 77, 2000 2-Naphthylamine 1–22 ng Sufficient 2B 40, 1986b; S7, 1987 4-Amode 2-5 ng Sufficient 2B 40, 1986b; S7, 1987 Heterocyclic aromatic amines - - - - Ac- 2-37 ng Sufficient 2B 40, 1986b; S7, 1987 IQ 0.3 ng Sufficient 2B 31, 1983b; S7,		C					
N-Nitrosonomicotine 154–196 ng Sufficient Limited 1 37, 1985; 57, 1987; 89, 200 4-(Methylnitrosamino)-1- 110–133 ng Sufficient Limited 1 37, 1985; 57, 1987; 89, 200 Aromatic amines - <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td>		-					
4-(Methylnitrosamino)-1- 110–133 ng Sufficient Limited 1 37, 1985; 57, 1987; 89, 200- (3-pyridyl)-1-butanone Aromatic amines - <td< td=""><td></td><td>•</td><td></td><td></td><td></td><td></td></td<>		•					
(3-pyridyl)-1-butanone Aromatic annines 2-Toluidine 30-200 ng Sufficient Limited 2A S7, 1987; 77, 2000 2,6-Dimethylaniline 4-50 ng Sufficient 2B 57, 1993 2-Naphthylamine 1-22 ng Sufficient Sufficient 1 4, 1974; S7, 1987 4-Aminobiphenyl 2-5 ng Sufficient Sufficient 1 1, 1972; S7, 1987 Heterocyclic aromatic amines - -37 ng Sufficient 2B 40, 1986b; S7, 1987 MeA-a-C 2-37 ng Sufficient 2B 40, 1986b; S7, 1987 IQ 0.3 ng Sufficient 2B 31, 1983b; S7, 1987 IQ 0.3 ng Sufficient 2B 31, 1983b; S7, 1987 IQ 0.3 ng Sufficient 2B 31, 1983b; S7, 1987 ITp-P-1 0.3-0.5 ng Sufficient 2B 40, 1986b; S7, 1987 IQ 0.8-1.1 ng Sufficient 2B 40, 1986b; S7, 1987 Glu-P-1 0.37-0.89 ng Sufficient 2B 40, 1986b; S7, 1987 Glu-P-2 0.25-0.88 ng Sufficient </td <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td>		-					
Aromatic amines 2 Toluidine 30–200 ng Sufficient Limited 2A S7, 1987; 77, 2000 2,6-Dimethylanilne 4–50 ng Sufficient 2B 57, 1993 2-Naphthylamine 1–22 ng Sufficient Sufficient 1 4, 1974; S7, 1987 4-Aminobiphenyl 2–5 ng Sufficient Sufficient 1 1, 1972; S7, 1987 Heterocyclic aromatic amines - - 25–260 ng Sufficient 2B 40, 1986b; S7, 1987 McA-α-C 2–37 ng Sufficient 2B 40, 1986b; S7, 1987 10 IQ 0.3 ng Sufficient 2B 31, 1983b; S7, 1987 IQ 0.3–0.5 ng Sufficient 2B 31, 1983b; S7, 1987 Glu-P-1 0.3–0.5 ng Sufficient 2B 40, 1986b; S7, 1987 Glu-P-2 0.8–1.1 ng Sufficient 2B 40, 1986b; S7, 1987 Glu-P-1 0.37–0.89 ng Sufficient 2B 40, 1986b; S7, 1987 Glu-P-2 0.25–0.88 ng Sufficient 2B 56, 1993b Aldehyde 70–864 µg Sufficient 2B		110–133 ng	Sufficient	Limited	1	37, 1985; 57, 1987; 89, 2004	
2-Toluidine30–200 ngSufficientLimited2AS7, 1987; 77, 20002,6-Dimethylaniline4–50 ngSufficient2B57, 19932-Naphthylamine1–22 ngSufficientSufficient14, 1974; S7, 19874-Aminobiphenyl2–5 ngSufficientSufficient11, 1972; S7, 1987Heterocyclic aromatic aminesSufficient2B40, 1986b; S7, 1987MeA- α -C25–260 ngSufficient2B40, 1986b; S7, 1987IQ0.3 ngSufficient2B40, 1986b; S7, 1987IQ0.3 ngSufficient2B31, 1983b; S7, 1987ITp-P-10.3–0.5 ngSufficient2B31, 1983b; S7, 1987Glu-P-10.37–0.89 ngSufficient2B40, 1986b; S7, 1987Glu-P-20.25–0.88 ngSufficient2B40, 1986b; S7, 1987JPhIP11–23 ngSufficient2B40, 1986b; S7, 1987Actealdehyde70–864 µgSufficient2B57, 1987; 71, 1999Phenolic compoundsCafteck acid59–81 µgSufficientSufficient2B57, 1987; 71, 1999Volatile hydrocarbons2B60, 1993bVolatile hydrocarbons2B60, 1993bNitronydydocarbons-2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994; 71, 199							
2,6-Dimethylaniline4–50 ngSufficient2B57, 19932-Naphthylamine1–22 ngSufficientSufficient14, 1974; 57, 19874-Aminobiphenyl2–5 ngSufficientSufficient11, 1972; 57, 1987Heterocyclic aromatic amines $-5 ng$ SufficientSufficient11, 1972; 57, 1987A- α -C25–260 ngSufficient2B40, 1986b; 57, 1987MeA- α -C2-37 ngSufficient2B40, 1986b; 57, 1987IQ0.3 ngSufficient2B31, 1983b; 57, 1987IQ0.3-0.5 ngSufficient2B31, 1983b; 57, 1987Trp-P-10.3–0.5 ngSufficient2B31, 1983b; 57, 1987Glu-P-10.37–0.89 ngSufficient2B40, 1986b; 57, 1987Glu-P-20.25–0.88 ngSufficient2B40, 1986b; 57, 1987JhPhP11–23 ngSufficient2B56, 1993bAldehydes770–864 µgSufficient2B57, 1987; 62,1995aAcetol59–81 µgSufficient2B57, 1987; 71, 1999Phenolic compounds -2 $2-40$ µgSufficient2B56, 1993bVolatile hydrocarbons -3 µgSufficient2B60, 1994; 71, 1999Isoprene450–1,000 µgSufficient2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994; 71, 1999Nitrohydrocarbons $-$							
2-Naphthylamine1–22 ngSufficientSufficient14, 1974; S7, 19874-Aminobiphenyl2–5 ngSufficientSufficient11, 1972; S7, 1987Heterocyclic aromatic amines $A - \alpha - C$ 25–260 ngSufficient2B40, 1986b; S7, 1987MeA- $\alpha - C$ 2–37 ngSufficient2B40, 1986b; S7, 1987IQ0.3 ngSufficient2AS7, 1987; 56, 1993Trp-P-10.3–0.5 ngSufficient2B31, 1983b; S7, 1987Glu-P-10.37–0.89 ngSufficient2B40, 1986b; S7, 1987Glu-P-20.8–1.1 ngSufficient2B40, 1986b; S7, 1987Glu-P-20.25–0.88 ngSufficient2B40, 1986b; S7, 1987PhIP11–23 ngSufficient2B40, 1986b; S7, 1987Addehydes770–864 µgSufficient2BS7, 1987; 71, 1999Phenolic compoundsCatechol59–81 µgSufficient2B56, 1993bVolatile hydrocarbons12, 1987; 71, 1999Sufficient2B60, 1994; 71, 1999I_3-Butadiene20–40 µgSufficient2B60, 1994; 71, 1999Isoprene450–1,000 µgSufficient2B60, 1994; 71, 1999Isoprene12–50 µgSufficient2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994; 71, 1999Isoprene450–1,000 µgSufficient2B60, 1994; 71, 1999Benzene12–50 µgSufficient2B60, 1994;		-		Limited			
4-Aminobiphenyl2–5 ngSufficientSufficient1 $I, 1972; S7, 1987$ Heterocyclic aromatic amines	-	C				-	
Heterocyclic aromatic aminesA- α -C25-260 ngSufficient2B40, 1986b; S7, 1987MeA- α -C2-37 ngSufficient2B40, 1986b; S7, 1987IQ0.3 ngSufficient2AS7, 1987; 56, 1993Trp-P-10.3-0.5 ngSufficient2B31, 1983b; S7, 1987Glu-P-10.3-0.5 ngSufficient2B31, 1983b; S7, 1987Glu-P-10.37-0.89 ngSufficient2B40, 1986b; S7, 1987Glu-P-20.25-0.88 ngSufficient2B40, 1986b; S7, 1987PhIP11-23 ngSufficient2B56, 1993bAldehydes70-864 µgSufficientSufficient1S7, 1987; 62, 1995aAcetaldehyde10.3-25 µgSufficientSufficient1S7, 1987; 71, 1999Phenolic compounds2B57, 1987; 71, 19992B57, 1987; 71, 1999Catechol59-81 µgSufficient2B56, 1993bVolatile hydrocarbons129, 98, 17, 19992B56, 1993bVolatile hydrocarbons2B60, 1994; 71, 199929, 1982; 57, 1987Isoprene12-50 µgSufficient2B60, 1994; 71, 1999Isoprene12-50 µgSufficientSufficient129, 1982; 57, 1987Nitromethane0.5-0.6 µgSufficientSufficient129, 1982; 57, 1987		-					
A- α -C25–260 ngSufficient2B40, 1986b; 57, 1987MeA- α -C2–37 ngSufficient2B40, 1986b; 57, 1987IQ0.3 ngSufficient2A57, 1987; 56, 1993Trp-P-10.3–0.5 ngSufficient2B31, 1983b; 57, 1987Trp-P-20.8–1.1 ngSufficient2B40, 1986b; 57, 1987Glu-P-10.37–0.89 ngSufficient2B40, 1986b; 57, 1987Glu-P-20.25–0.88 ngSufficient2B40, 1986b; 57, 1987PhIP11–23 ngSufficient2B56, 1993bAldehydes70–864 µgSufficient2B57, 1987; 62, 1995aAcetaldehyde70–864 µgSufficient2B57, 1987; 71, 1999Phenolic compounds2B57, 1987; 71, 19992BCaffeic acid59–81 µgSufficient2B56, 1993bVolatile hydrocarbons12B56, 1993bVolatile hydrocarbons12B56, 1993bNitromethane12–50 µgSufficientLimited2A57, 1987; 71, 1999Soprene450–1,000 µgSufficientLimited2A57, 1987; 71, 1999Isoprene12–50 µgSufficientSufficient2B60, 1994; 71, 1999Isoprene12–50 µgSufficientSufficient129, 1982; S7, 1987Nitrohydrocarbons129, 1982; S7, 1987Sufficient129, 1982; S7, 1987		2–5 ng	Sufficient	Sufficient	1	1, 1972; <i>S7</i> , 1987	
MeA- α -C2–37 ngSufficient2B40, 1986b; 57, 1987IQ0.3 ngSufficient2AS7, 1987; 56, 1993Trp-P-10.3–0.5 ngSufficient2B31, 1983b; 57, 1987Trp-P-20.8–1.1 ngSufficient2B31, 1983b; 57, 1987Glu-P-10.37–0.89 ngSufficient2B40, 1986b; 57, 1987Glu-P-20.25–0.88 ngSufficient2B40, 1986b; 57, 1987PhIP11–23 ngSufficient2B40, 1986b; 57, 1987AldehydesFormaldehyde10.3–25 µgSufficient2B56, 1993bAcetaldehyde770–864 µgSufficient2B57, 1987; 71, 1999Phenolic compoundsCatechol59–81 µgSufficient2B56, 193bVolatile hydrocarbonsII23, 1987; 71, 19991999I,3-Butadiene20–40 µgSufficientLimited2AS7, 1987; 71, 1999Isoprene450–1,000 µgSufficientSufficient2B60, 1994; 71, 1999Isoprene12–50 µgSufficientSufficient129, 1982; S7, 1987Nitromethane0.5–0.6 µgSufficientSufficient129, 1982; S7, 1987	•						
IQ0.3 ngSufficient2A $S7$, 1987; 56, 1993Trp-P-10.3-0.5 ngSufficient2B $3I$, 1983b; $S7$, 1987Trp-P-20.8-1.1 ngSufficient2B $3I$, 1983b; $S7$, 1987Glu-P-10.37-0.89 ngSufficient2B 40 , 1986b; $S7$, 1987Glu-P-20.25-0.88 ngSufficient2B 40 , 1986b; $S7$, 1987PhIP11-23 ngSufficient2B 56 , 1993bAldehydesSufficientSufficient1Formaldehyde10.3-25 µgSufficientSufficient2B $S7$, 1987; 62 , 1995aAcetaldehyde70-864 µgSufficient2B $S7$, 1987; $7I$, 1999Phenolic compounds2B $S7$, 1987; $7I$, 1999Caffeic acid59-81 µgSufficient2B $S7$, 1987; $7I$, 1999Caffeic acid59-81 µgSufficient2B $S7$, 1987; $7I$, 1999Volatile hydrocarbons2B 60 , 1993bI,3-Butadiene20-40 µgSufficientLimited2A $S7$, 1987; $7I$, 1999Benzene12-50 µgSufficientSufficient1 29 , 1982; $S7$, 1987NitrohydrocarbonsSufficientSufficient1 29 , 1982; $S7$, 1987Nitromethane0.5-0.6 µgSufficientSufficient2B 77 , 2000		e e					
Trp-P-1 $0.3-0.5 \text{ ng}$ Sufficient $2B$ $31, 1983b; S7, 1987$ Trp-P-2 $0.8-1.1 \text{ ng}$ Sufficient $2B$ $31, 1983b; S7, 1987$ Glu-P-1 $0.37-0.89 \text{ ng}$ Sufficient $2B$ $40, 1986b; S7, 1987$ Glu-P-2 $0.25-0.88 \text{ ng}$ Sufficient $2B$ $40, 1986b; S7, 1987$ PhIP $11-23 \text{ ng}$ Sufficient $2B$ $56, 1993b$ Aldehydes </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Tp-P-2 $0.8-1.1 \text{ ng}$ Sufficient $2B$ $31, 1983b; S7, 1987$ Glu-P-1 $0.37-0.89 \text{ ng}$ Sufficient $2B$ $40, 1986b; S7, 1987$ Glu-P-2 $0.25-0.88 \text{ ng}$ Sufficient $2B$ $40, 1986b; S7, 1987$ PhIP $11-23 \text{ ng}$ Sufficient $2B$ $56, 1993b$ Aldehydes $57, 1987, 62, 1995a$ Sufficient 1 $57, 1987; 62, 1995a$ Acetaldehyde $70-864 \mu g$ Sufficient $2B$ $57, 1987; 71, 1999$ Phenolic compounds $70-864 \mu g$ Sufficient $2B$ $57, 1987; 71, 1999$ Catechol $59-81 \mu g$ Sufficient $2B$ $56, 1993b$ Volatile hydrocarbons $3 \mu g$ Sufficient $2B$ $56, 1993b$ Volatile hydrocarbons $13-80 ext{utalene}$ $20-40 \ \mu g$ SufficientLimited $2A$ $57, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ Nitrohydrocarbons $12-50 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ Nitromethane $0.5-0.6 \ \mu g$ Sufficient $2B$ $77, 2000$							
Glu-P-1 $0.37-0.89$ ngSufficient $2B$ $40, 1986b; S7, 1987$ Glu-P-2 $0.25-0.88$ ngSufficient $2B$ $40, 1986b; S7, 1987$ PhIP $11-23$ ngSufficient $2B$ $56, 1993b$ AldehydesFormaldehyde $10.3-25 \ \mu g$ SufficientSufficient 1 $S7, 1987; 62, 1995a$ Acetaldehyde $70-864 \ \mu g$ Sufficient $2B$ $S7, 1987; 71, 1999$ Phenolic compounds ZB $S7, 1987; 71, 1999$ Catechol $59-81 \ \mu g$ Sufficient $2B$ $56, 1993b$ Volatile hydrocarbons ZB $S7, 1987; 71, 1999$ I,3-Butadiene $20-40 \ \mu g$ SufficientLimited $2A$ $S7, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ SufficientSufficient $2B$ $60, 1994; 71, 1999$ Benzene $12-50 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ Nitrohydrocarbons V SufficientSufficient 1 $29, 1982; S7, 1987$		•					
Glu-P-2 $0.25-0.88$ ngSufficient2B $40, 1986b; S7, 1987$ PhIP $11-23$ ngSufficient2B $56, 1993b$ AldehydesFormaldehyde $10.3-25 \ \mu g$ SufficientSufficient1 $S7, 1987; 62, 1995a$ Acetaldehyde $770-864 \ \mu g$ Sufficient2B $S7, 1987; 71, 1999$ Phenolic compounds ZB $S7, 1987; 71, 1999$ Catechol $59-81 \ \mu g$ Sufficient2B $56, 1993b$ Caffeic acid $59-81 \ \mu g$ Sufficient2B $56, 1993b$ Volatile hydrocarbons ZB $56, 1993b$ $S7, 1987; 71, 1999$ Isoprene $20-40 \ \mu g$ SufficientLimited2A $S7, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ SufficientLimited2B $60, 1994; 71, 1999$ Benzene $12-50 \ \mu g$ SufficientSufficient1 $29, 1982; S7, 1987$ NitrohydrocarbonsNitromethane $0.5-0.6 \ \mu g$ Sufficient2B $77, 2000$	1	-					
PhIP $11-23$ ngSufficient2B56, 1993bAldehydesFormaldehyde $10.3-25$ μgSufficientSufficient1 $S7$, 1987; 62, 1995aAcetaldehyde $770-864$ μgSufficient2B $S7$, 1987; 71, 1999Phenolic compounds $2B$ $S7$, 1987; 71, 1999Catechol $59-81$ μgSufficient2B $S7$, 1987; 71, 1999Caffeic acid <3 μgSufficient2B 56 , 1993bVolatile hydrocarbons I I I $S7$, 1987; 71, 1999Isoprene $20-40$ μgSufficientLimited $2A$ $S7$, 1987; 71, 1999Isoprene $450-1,000$ μgSufficientLimited $2A$ $S7$, 1987; 71, 1999Benzene $12-50$ μgSufficientSufficient1 29 , 1982; S7, 1987Nitrohydrocarbons I $S1-0.6$ μgSufficient $S1$ $2B$ 77 , 2000		-					
AldehydesFormaldehyde $10.3-25 \ \mu g$ SufficientSufficient1 $S7, 1987; 62, 1995a$ Acetaldehyde $770-864 \ \mu g$ Sufficient2B $S7, 1987; 71, 1999$ Phenolic compounds $2B$ $S7, 1987; 71, 1999$ Catechol $59-81 \ \mu g$ Sufficient2B $S7, 1987; 71, 1999$ Caffeic acid $<3 \ \mu g$ Sufficient2B $56, 1993b$ Volatile hydrocarbons I I I $S7, 1987; 71, 1999$ Isoprene $20-40 \ \mu g$ SufficientLimited $2A$ $S7, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ Sufficient $2B$ $60, 1994; 71, 1999$ Benzene $12-50 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ Nitrohydrocarbons I $S0-0.6 \ \mu g$ Sufficient $Sufficient$ $2B$ $77, 2000$		•					
Formaldehyde $10.3-25$ μgSufficientSufficient1 $S7$, 1987; 62, 1995aAcetaldehyde $70-864$ μgSufficient2B $S7$, 1987; 71, 1999Phenolic compounds $59-81$ μgSufficient2B $S7$, 1987; 71, 1999Caffeic acid $59-81$ μgSufficient2B 56 , 1993bVolatile hydrocarbons 3 μgSufficientLimited2A 57 , 1987; 71, 1999Isoprene $20-40$ μgSufficientLimited2A $S7$, 1987; 71, 1999Isoprene $450-1,000$ μgSufficientSufficient2B 60 , 1994; 71, 1999Benzene $12-50$ μgSufficientSufficient1 29 , 1982; S7, 1987NitrohydrocarbonsNitromethane $0.5-0.6$ μgSufficient2B 77 , 2000	PhIP	11–23 ng	Sufficient		2B	56, 1993b	
Acetaldehyde $770-864 \ \mu g$ Sufficient $2B$ $S7, 1987; 71, 1999$ Phenolic compounds $59-81 \ \mu g$ Sufficient $2B$ $S7, 1987; 71, 1999$ Caffeic acid $59-81 \ \mu g$ Sufficient $2B$ $56, 1993b$ Caffeic acid $<3 \ \mu g$ Sufficient $2B$ $56, 1993b$ Volatile hydrocarbons I I I $S7, 1987; 71, 1999$ Isoprene $20-40 \ \mu g$ SufficientLimited $2A$ $S7, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ Sufficient $2B$ $60, 1994; 71, 1999$ Benzene $12-50 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ Nitrohydrocarbons I I $SIFICIENTIIINitromethane0.5-0.6 \ \mu gSufficient2B77, 2000$	Aldehydes						
Phenolic compounds Sufficient 2B S7, 1987; 71, 1999 Catechol 59–81 μg Sufficient 2B 56, 1993b Caffeic acid <3 μg		10.3–25 µg		Sufficient	1	<i>S7</i> , 1987;62,1995a	
Catechol $59-81 \ \mu g$ Sufficient $2B$ $S7, 1987; 71, 1999$ Caffeic acid $<3 \ \mu g$ Sufficient $2B$ $56, 1993b$ Volatile hydrocarbons $1,3$ -Butadiene $20-40 \ \mu g$ SufficientLimited $2A$ $S7, 1987; 71, 1999$ Isoprene $450-1,000 \ \mu g$ Sufficient $2B$ $60, 1994; 71, 1999$ Benzene $12-50 \ \mu g$ SufficientSufficient 1 $29, 1982; S7, 1987$ NitrohydrocarbonsNitromethane $0.5-0.6 \ \mu g$ Sufficient $2B$ $77, 2000$	Acetaldehyde	770–864 μg	Sufficient		2B	S7, 1987; 71, 1999	
Caffeic acid <3 μg Sufficient 2B 56, 1993b Volatile hydrocarbons 1,3-Butadiene 20-40 μg Sufficient Limited 2A S7, 1987; 71, 1999 Isoprene 450–1,000 μg Sufficient 2B 60, 1994; 71, 1999 Benzene 12–50 μg Sufficient Sufficient 1 29, 1982; S7, 1987 Nitrohydrocarbons Nitromethane 0.5–0.6 μg Sufficient 2B 77, 2000	Phenolic compounds						
Volatile hydrocarbons 1,3-Butadiene 20-40 μg Sufficient Limited 2A S7, 1987; 71, 1999 Isoprene 450-1,000 μg Sufficient 2B 60, 1994; 71, 1999 Benzene 12-50 μg Sufficient Sufficient 1 29, 1982; S7, 1987 Nitrohydrocarbons Nitromethane 0.5-0.6 μg Sufficient 2B 77, 2000	Catechol	59–81 μg	Sufficient		2B	<i>S7</i> , 1987; <i>71</i> , 1999	
1,3-Butadiene 20–40 μg Sufficient Limited 2A S7, 1987; 71, 1999 Isoprene 450–1,000 μg Sufficient 2B 60, 1994; 71, 1999 Benzene 12–50 μg Sufficient Sufficient 1 29, 1982; S7, 1987 Nitrohydrocarbons Nitromethane 0.5–0.6 μg Sufficient 2B 77, 2000	Caffeic acid	<3 µg	Sufficient		2B	<i>56</i> , 1993b	
Isoprene 450–1,000 μg Sufficient 2B 60, 1994; 71, 1999 Benzene 12–50 μg Sufficient Sufficient 1 29, 1982; S7, 1987 Nitrohydrocarbons Nitromethane 0.5–0.6 μg Sufficient 2B 77, 2000	Volatile hydrocarbons						
Benzene12–50 μgSufficientSufficient129, 1982; S7, 1987NitrohydrocarbonsNitromethane0.5–0.6 μgSufficient2B77, 2000	1,3-Butadiene	20–40 µg	Sufficient	Limited	2A	S7, 1987; 71, 1999	
Benzene12–50 μgSufficientSufficient129, 1982; S7, 1987NitrohydrocarbonsNitromethane0.5–0.6 μgSufficient2B77, 2000	Isoprene	450–1,000 μg	Sufficient		2B	60, 1994; 71, 1999	
Nitrohydrocarbons Nitromethane 0.5–0.6 µg Sufficient 2B 77, 2000	-	. –	Sufficient	Sufficient	1		
Nitromethane 0.5–0.6 µg Sufficient 2B 77, 2000	Nitrohydrocarbons						
	-	0.5–0.6 µg	Sufficient		2B	77, 2000	
	2-Nitropropane	0.7–1.2 ng	Sufficient		2B	<i>S7</i> , 1987; <i>71</i> , 1999	

Table 4 (continued)

Carcinogen	Amount in mainstream cigarette smoke	IARC Monog of carcinoger	<i>raphs</i> evaluation	Monograph volume, year	
		In animals	In humans	IARC Group	
Nitrobenzene	25 μg	Sufficient		2B	65, 1996
Miscellaneous organic compou	nds				
Acetamide	38–56 μg	Sufficient		2B	S7, 1987; 71, 1999
Acrylamide	Present	Sufficient		2A	S7, 1987; 60, 1994
Acrylonitrile	3–15 µg	Sufficient		2B	S7, 1987; 71, 1999
Vinyl chloride	11–15 ng	Sufficient	Sufficient	1	19, 1979; S7, 1987
1,1-Dimethylhydrazine	Present	Sufficient		2B	4, 1974; 71, 1999
Ethylene oxide	7 μg	Sufficient	Limited	1	60, 1994; S7,1987
Propylene oxide	0–100 ng	Sufficient		2B	60, 1994; S7, 1987
Urethane	20–38 ng	Sufficient		2B	7, 1974; <i>S7</i> , 1987
Metals and inorganic compoun	ds				
Arsenic	40–120 ng	Sufficient	Sufficient	1	<i>84</i> , 2004a
Beryllium	0.5 ng	Sufficient	Sufficient	1	S7, 1987; 58, 1993a
Nickel	ND-600 ng	Sufficient	Sufficient	1	S7, 1987; 49, 1990
Chromium (hexavalent)	4–70 ng	Sufficient	Sufficient	1	S7, 1987; 49, 1990
Cadmium	41–62 ng	Sufficient	Sufficient	1	S7, 1987; 58, 1993a
Cobalt	0.13-0.20 ng	Sufficient		2B	52, 1991
Lead (inorganic)	34–85 ng	Sufficient	Limited	2A	23, 1980; S7,1987; 87, 2004
Hydrazine	24–43 ng	Sufficient		2B	S7, 1987; 71, 1999
Radio-isotope Polonium-210	0.03–1.0 pCi	Sufficient		1	78, 2001

This table (modified from Hoffmann et al., 2001 [40] and IARC volume 83 [2]) shows components of unfiltered mainstream cigarette smoke, with amounts given per cigarette. Virtually all these compounds are known carcinogens in experimental animals. In combination with data on cancer in humans and—in some cases—other relevant data, IARC Monographs classifications for these agents have been established as Group 2B (possibly carcinogenic to humans), Group 2A (probably carcinogenic to humans), or Group 1 (carcinogenic to humans). When IARC evaluations were made more than twice, only the two most recent Monographs are listed, with volume number and year of publication. No entry in the column 'humans' indicates inadequate evidence or no data.

S7 Supplement 7 of the *IARC Monographs*, *ND* not detected, $A - \alpha - C$ 2-amino-9*H*-pyrido[2,3-*b*]indole, *MeA*- α -*C* 2-amino-3-methyl-9*H*-pyrido [2,3-*b*]indole, *IQ* 2-amino-3-methylimidazo[4,5-*b*]quinoline, *Trp-P-1* 3-amino-1,4-dimethyl-5*H*-pyrido[4,3-*b*]indole, *Trp-P-2* 3-amino-1-methyl-5*H*-pyrido[4,3-*b*]indole, *GIu-P-1* 2-amino-6-methyl[1,2-*a*:3',2"-*d*]imidazole, *GIu-P-2* 2-aminodipyrido[1,2-*a*:3',2"-*d*]imidazole, *PhIP* 2-amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine, *pCi* picoCurie

cigarette smoke. Among the well characterized compounds in Table 4, the most important, based on their carcinogenic potency and levels in cigarette smoke are probably PAH, *N*-nitrosamines, aromatic amines, 1,3-butadiene, benzene, aldehydes, and ethylene oxide. The same carcinogens are also present in secondhand cigarette smoke, but human exposure is considerably less due to dilution with ambient air.

The role of carcinogens in specific cancers caused by cigarette smoke

Although difficult to prove, data from carcinogenicity studies, product analyses, and biochemical and molecular biological investigations do support a significant role for certain carcinogens in specific types of cancer (Table 5). Considerable evidence favors PAH and NNK as major etiological factors in lung cancer. PAH are strong locally acting carcinogens, and tobacco smoke fractions enriched in these compounds are carcinogenic [10, 29, 30]. PAH–DNA

Table 5 Carcinogens and tobacco-induced cancers

Cancer type	Likely carcinogen involvement ^a
Lung	PAH, NNK (major);1,3-butadiene, isoprene, ethylene oxide, ethyl carbamate, aldehydes, benzene, metals
Larynx	РАН
Nasal	NNK, NNN, other N-nitrosamines, aldehydes
Oral cavity	PAH, NNK, NNN
Esophagus	NNN, other N-nitrosamines
Liver	NNK, other N-nitrosamines, furan
Pancreas	NNK, NNAL
Cervix	PAH, NNK
Bladder	4-aminobiphenyl, other aromatic amines
Leukemia	Benzene

^a Based on carcinogenicity studies in laboratory animals, biochemical evidence from human tissues and fluids, and epidemiological data, where available

NNAL 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, NNK 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone, NNN N'-nitrosonomicotine, PAH polycyclic aromatic hydrocarbons

Adapted from Surgeon General's Report 2006, in preparation.

adducts have been detected in human lung, and the spectrum of mutations in the *TP53* tumor suppressor gene isolated from lung tumors is similar to the spectrum of DNA damage produced in vitro by PAH metabolites and in cell culture by BaP [31–34].

NNK is a strong systemic lung carcinogen in rodents, inducing lung tumors independently of its route of administration [15]. The strength of NNK is particularly great in the rat, in which total doses as low as 6 mg/kg (and 1.8 mg/kg when considered as part of a doseresponse trend) induce a significant incidence of lung tumors [35]. This compares to an estimated 1.1 mg/kg dose of NNK in humans in 40 years of smoking [15]. DNA adducts derived from NNK or the related tobacco-specific nitrosamine NNN are present in lung tissue from smokers, and metabolites of NNK are present in smokers' urine [36]. Epidemiologic data indicate that a systemic carcinogen causes lung cancer in cigar smokers who do not inhale, consistent with the systemic tumorigenic properties of NNK [37, 38]. The changing histology of lung cancer, in which adenocarcinoma has now overtaken squamous cell carcinoma as the most common lung cancer type, is also consistent with the role of NNK, which produces primarily adenocarcinoma in rodents, although this has also been attributed to differing inhalation patterns of current cigarettes [15, 39]. NNK concentrations in mainstream smoke increased, while those of BaP decreased, as nitrate concentrations in tobacco increased over the period of 1959-1997 due to the use of tobacco blends containing higher levels of air-cured tobacco, use of reconstituted tobacco, and other factors [40]. Other compounds that could be involved in lung cancer include 1,3-butadiene, isoprene, ethylene oxide, ethyl carbamate, aldehydes, benzene, metals, and oxidants, but the collective evidence for each of these is not as strong as for PAH and NNK [26].

The particulate phase of cigarette smoke causes tumors of the larynx in hamsters—this could be attributed to PAH [41]. *TP53* gene mutations identified in tumors of the human larynx are consistent with a role for PAH [31]. *N*-Nitrosamines and acetaldehyde and formaldehyde, induce nasal tumors in rodents and are likely candidates as causes of smoking associated nasal tumors [13, 19, 22]. PAH, NNK, and NNN are the most likely causes of oral cancer in smokers based on animal studies [42]. *N*-Nitrosamines are the most effective esophageal carcinogens known, and NNN, which causes tumors of the esophagus in rats, is the most prevalent *N*-nitrosamine carcinogen in cigarette smoke [43, 44].

NNK and several other *N*-nitrosamines in cigarette smoke are effective hepatocarcinogens in rats, as is furan [13, 45]. NNK and its major metabolite NNAL are the only pancreatic carcinogens known to be present in tobacco products. Biochemical data from studies with human tissues provide some support for their role in smoking related pancreatic cancer, although DNA adducts were not detected [46-48]. Biochemical studies demonstrate that both NNK and PAH can reach the cervix in humans, and are metabolically activated there [49, 50]. DNA adducts derived from BaP and other hydrophobic compounds have been detected in cervical tissue from smokers [33, 50]. Therefore, these compounds might contribute to the etiology of cervical cancer in smokers, in combination with human papilloma virus [51]. 4-Aminobiphenyl and 2-naphthylamine are known human bladder carcinogens, and considerable data support the role of aromatic amines as major causes of bladder cancer in smokers [52–57]. The most probable cause of leukemia in smokers is benzene, which occurs in large quantities in cigarette smoke, and is a known cause of acute myelogenous leukemia in humans [23]. Cigarette smoke also causes oxidative damage, probably because it contains free radicals such as nitric oxide and mixtures of hydroquinones, semiquinones, and quinones [26, 58]. Smokers have lower levels of ascorbic acid and sometimes higher levels of oxidized DNA bases than non-smokers but the role of oxidative damage as a cause of specific tobacco-induced cancers remains unclear [26].

Overview of mechanisms of tumor induction by cigarette smoke

Figure 3 gives a schematic overview of the mechanisms by which cigarette smoke causes cancer [26]. The central track of Fig. 3, involving exposure to carcinogens, the formation of covalent bonds between the carcinogens and DNA producing DNA adducts, and the resulting permanent mutations in critical genes of somatic cells is the major established pathway of cancer causation by cigarette smoke. Somatic mutations occur in somatic cells, and therefore, affect only their descendants and are not inherited. The somatic mutation theory of cancer is well established, and the presence of multiple mutagenic carcinogens in cigarette smoke is completely consistent with this theory.

Most people start smoking as teenagers, generally due to peer pressure. Some become addicted to nicotine and then smoke habitually. While nicotine, the main known addictive agent in cigarette smoke, is not carcinogenic, each puff of each cigarette contains a mixture of well established carcinogens (Table 4), along with thousands of other compounds. Extensive data demonstrate the uptake of these carcinogens by smokers and confirm the expected higher levels of their metabolites than in nonsmokers.

Most cigarette smoke carcinogens require a metabolic activation process, generally catalyzed by cytochrome P450 enzymes (P450s), to convert them to electrophilic entities that can covalently bind to DNA, forming DNA adducts [59, 60]. P450s 1A1 and 1B1, which are inducible by




Fig. 3 Scheme linking nicotine addiction and cancer via tobacco smoke carcinogens

cigarette smoke via interactions with the aryl hydrocarbon receptor, are particularly important in the metabolic activation of PAH [61]. The inducibility of these P450s may be a critical aspect of cancer susceptibility in smokers. P450s 1A2, 2A13, 2E1, and 3A4 are also important in the activation of cigarette smoke carcinogens. Competing with the activation process is metabolic detoxification, which results in excretion of carcinogen metabolites in generally harmless forms, and is catalyzed by a variety of enzymes including glutathione-S-transferases and UDP-glucuronosyl transferases [62, 63]. The balance between carcinogen metabolic activation and detoxification varies among individuals and is likely to affect cancer susceptibility with those having higher activation and lower detoxification capacity being at highest risk. This is supported, in part, by evidence from molecular epidemiologic studies of polymorphisms or variants in these enzymes [64].

Continuing along the central track of Fig. 3, the metabolic activation of carcinogens results in the formation of DNA adducts, and these are absolutely central to the carcinogenic process. Starting in the mid-1980s, extensive studies examined the presence of DNA adducts in human tissues. There is massive evidence, particularly from studies which use relatively nonspecific adduct measurement methods, that adduct levels in the lung and other tissues are higher in smokers than in nonsmokers, and some epidemiologic data link higher adduct levels with a higher probability of cancer development [3].

Cellular repair systems can remove DNA adducts and return the structure of DNA to normal. These include direct base repair by alkyltransferases, excision of DNA damage by base and nucleotide excision repair, mismatch repair, and double strand repair. If these repair enzymes are overwhelmed by DNA damage or for other reasons cannot efficiently perform their function, then adducts may persist, leading to a higher probability of cancer development. There are polymorphisms in some DNA repair enzymes and the resulting deficient DNA repair can lead to a higher probability of cancer development, a subject of current interest in molecular epidemiology [65].

Persistent DNA adducts can cause miscoding during replication when DNA polymerase enzymes process them incorrectly. There is considerable specificity in the relationship between DNA adducts caused by cigarette smoke carcinogens and the types of mutations which they cause. G to T and G to A mutations are frequently observed [26]. Mutations have been seen frequently in the KRAS oncogene in lung cancer and in the TP53 tumor suppressor gene in a variety of cigarette smoke-induced cancers [31, 66]. The cancer-causing role of these genes has been firmly established in animal studies [67, 68]. The KRAS and TP53 mutations observed in lung cancer in smokers appear to reflect DNA damage by metabolically activated PAH, although other carcinogens are also likely to be involved. In addition, numerous cytogenetic changes have been observed in lung cancer, and chromosome damage throughout the aerodigestive tract is strongly linked with cigarette smoke exposure. Gene mutations can cause loss of normal cellular growth control functions, via a complex process of signal transduction pathways, ultimately resulting in genomic instability, cellular proliferation, and cancer [69, 70]. Apoptosis, or programmed cell death, is a protective process which can remove cells with DNA damage and serves as a counterbalance to these mutational events. The balance between mechanisms leading to apoptosis and those suppressing apoptosis has a major impact on tumor growth [70].

While the central track of Fig. 3 proceeding through genetic damage is clearly established as the major pathway by which cigarette smoke carcinogens cause cancer, epigenetic pathways also contribute, as indicated in the top and bottom tracks of Fig. 3 [71, 72]. Nicotine and tobacco-specific nitrosamines bind to nicotinic and other cellular receptors leading to activation of Akt (also known as protein kinase B), protein kinase A, and other changes, resulting in decreased apoptosis, increased angiogenesis, and increased transformation [73, 74]. Cigarette smoke

activates the epidermal growth factor receptor and cyclooxygenase-2 [75]. Furthermore, co-carcinogens and tumor promoters occur in cigarette smoke. Another important epigenetic pathway is enzymatic methylation of promoter regions of genes, which can result in gene silencing. If this occurs in tumor suppressor genes, the result can be unregulated proliferation [76].

Conclusion

The decrease in cigarette smoking in countries such as the U.S. results in a decrease in lung cancer and predicts a decrease in other tobacco-related cancers (Fig. 2). This is a very encouraging development, and the major successful methods of tobacco control-legislation to ban smoking in public places, increased taxation, and aggressive anti-tobacco advertising-must be continued. These policies have strongly influenced overall cancer mortality. The situation in developing countries is not as encouraging because tobacco use is increasing in many of these countries. Overall, cigarette smoking in the world continues to be pervasive and is unlikely to abate in the near future. Research on mechanisms of tobacco-induced cancer has provided a strong framework for understanding the actions of tobacco carcinogens (Fig. 3). We have an excellent understanding of the carcinogens in cigarette smoke, their metabolism to DNA adducts, and their competing detoxification pathways. We have also achieved an ever-increasing appreciation of the complex pathways that lead to genomic instability and ultimately to cancer due to the persistence of unrepaired DNA adducts in tissues of people who smoke cigarettes. These findings provide new insights for blocking key steps in the cancer induction process. It is hoped that these mechanistic insights will be translated into practical approaches for the prevention and cure of tobaccoinduced cancer.

Acknowledgements The author's research on cigarette smoking and cancer is supported by grants CA-81301, CA-92025, CA-102502, DA-13333, and ES-11297 from the U.S. National Institutes of Health and RP-00-138 from the American Cancer Society.

References

- 1. Mackay J, Eriksen M (2002) The tobacco atlas. World Health Organization, Geneva, pp 24–27
- International Agency for Research on Cancer (2004) Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. IARC, Lyon, FR, pp 53–119
- International Agency for Research on Cancer (2004) Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of carcinogenic risks to humans, vol 83. IARC, Lyon, FR, pp 1179–1187

- Centers for Disease Control (2005) Cigarette smoking among adults—United States, 2004. MMWR 54:1121–1124
- Wynder EL, Graham EA (1950) Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. A study of six hundred and eighty-four proved cases. JAMA 143:329–336
- Doll R, Hill AB (1950) Smoking and carcinoma of the lung. A preliminary report. Br Med J ii:739–748
- 7. U.S. Department of Health and Human Services (2004) The health consequences of smoking: a report of the surgeon general. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, Rockville, MD
- 8. U.S.Department of Health and Human Services (2006) The health consequences of involuntary exposure to tobacco smoke: a report of the surgeon general. U.S. Dept. of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Washington, DC, p 709
- 9. Phillips DH (1983) Fifty years of benzo[a]pyrene. Nature 303:468-472
- International Agency for Research on Cancer (1983) Polynuclear aromatic compounds, part 1, chemical, environmental, and experimental data. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 32. IARC, Lyon, FR, pp 33–91
- Dipple A, Moschel RC, Bigger CAH (1984) Polynuclear aromatic hydrocarbons. In: Searle CE (ed) Chemical carcinogens, second edition, ACS monograph 182, vol 1. American Chemical Society, Washington, D.C., pp 41–163
- Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Cogliano V (2005) Carcinogenicity of polycyclic aromatic hydrocarbons. Lancet Oncol 6:931–932
- Preussmann R, Stewart BW (1984) N-Nitroso carcinogens. In: Searle CE (ed) Chemical carcinogens, second edition, ACS monograph 182, vol 2. American Chemical Society, Washington, DC, pp 643–828
- Hecht SS, Hoffmann D (1988) Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9:875–884
- Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559–603
- International Agency for Research on Cancer (2006) Smokeless tobacco and tobacco-specific nitrosamines. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 89. IARC, Lyon, FR (in press)
- Luch A (2005) Nature and nurture—lessons from chemical carcinogenesis. Nat Rev Cancer 5:113–125
- Sugimura T (1995) History, present and future, of heterocyclic amines, cooked food mutagens. Princess Takamatsu Symp 23:214–231
- International Agency for Research on Cancer (1995) Wood dust and formaldehyde. IARC monographs on the evaluation of carcinogenic risks to humans, vol 62. IARC, Lyon, FR, pp 217–362
- 20. International Agency for Research on Cancer (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (Part Two). IARC monographs on the evaluation of carcinogenic risks to humans, vol 71. IARC, Lyon, FR, pp 319–451
- 21. International Agency for Research on Cancer (1993) Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 56. IARC, Lyon, FR, pp 115–134
- 22. International Agency for Research on Cancer (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide (part one). IARC monographs on the evaluation of carcinogenic risks to humans, vol 71. IARC, Lyon, FR, pp 109–225

- 23. International Agency for Research on Cancer (1982) Some industrial chemicals and dyestuffs. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 29. IARC, Lyon, FR, pp 93–148
- 24. International Agency for Research on Cancer (1979) Some monomers, plastics and synthetic elastomers, and acrolein. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 19. IARC, Lyon, FR, pp 377–438
- International Agency for Research on Cancer (1994) Some industrial chemicals. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 60. IARC, Lyon, FR, pp 73–159
- 26. Hecht SS (1999) Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91:1194–1210
- Carmella SG, Chen M, Villalta PW, Gurney JG, Hatsukami DK, Hecht SS (2002) Ethylation and methylation of hemoglobin in smokers and non-smokers. Carcinogenesis 23:1903–1910
- 28. Singh R, Kaur B, Farmer PB (2005) Detection of DNA damage derived from a direct acting ethylating agent present in cigarette smoke by use of liquid chromatography-tandem mass spectrometry. Chem Res Toxicol 18:249–256
- Hoffmann D, Schmeltz I, Hecht SS, Wynder EL (1978) Tobacco carcinogenesis. In: Gelboin H, Ts'o POP (eds) Polycyclic hydrocarbons and cancer. Academic, New York, pp 85–117
- Deutsch-Wenzel R, Brune H, Grimmer G (1983) Experimental studies in rat lungs on the carcinogenicity and dose–response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst 71:539–544
- Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435–7451
- Boysen G, Hecht SS (2003) Analysis of DNA and protein adducts of benzo[*a*]pyrene in human tissues using structure-specific methods. Mutat Res 543:17–30
- Phillips DH (2002) Smoking-related DNA and protein adducts in human tissues. Carcinogenesis 23:1979–2004
- 34. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65:2583–2587
- 35. Belinsky SA, Foley JF, White CM, Anderson MW, Maronpot RR (1990) Dose–response relationship between O⁶-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 50:3772–3780
- Hecht SS (2002) Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23:907–922
- 37. Shapiro JA, Jacobs EJ, Thun MJ (2000) Cigar smoking in men and risk of death from tobacco-related cancers. J Natl Cancer Inst 92:333–337
- 38. Boffetta P, Pershagen G, Jockel KH, Forastiere F, Gaborieau V, Heinrich J, Jahn I, Kreuzer M, Merletti F, Nyberg F, Rosch F, Simonato L (1999) Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 91:697–701
- 39. Travis WD, Travis LB, Devesa SS (1995) Lung cancer. Cancer 75:191–202
- Hoffmann D, Hoffmann I, El Bayoumy K (2001) The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem Res Toxicol 14:767–790
- International Agency for Research on Cancer (1986) Tobacco smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, vol 38. IARC, Lyon, FR, pp 37–385
- Hoffmann D, Hecht SS (1990) Advances in tobacco carcinogenesis. In: Cooper CS, Grover PL (eds) Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York, pp 63–102

- 43. Lijinsky W (1992) Chemistry and biology Of *N*-nitroso compounds. Cambridge University Press, Cambridge, England
- 44. Hecht SS, Hoffmann D (1989) The relevance of tobacco-specific nitrosamines to human cancer. Cancer Surv 8:273–294
- 45. International Agency for Research on Cancer (1995) Dry cleaning, some chlorinated solvents and other industrial chemicals. IARC monographs on the evaluation of carcinogenic risks to humans, vol 63. IARC, Lyon, France, pp 393–407
- 46. Prokopczyk B, Leder G, Trushin N, Cunningham AJ, Akerkar S, Pittman B, Ramadani M, Straeter J, Beger HG, Henne-Bruns D, El Bayoumy K (2005) 4-Hydroxy-1-(3-pyridyl)-1-butanone, an indicator for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced DNA damage, is not detected in human pancreatic tissue. Cancer Epidemiol Biomarkers Prev 14:540–541
- 47. Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS (1988) Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and *Areca*-derived *N*-nitrosamines. Cancer Res 48:6912–6917
- 48. Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, Boyiri T, Amin S, Desai D, Colosimo S, Pittman B, Leder G, Ramadani M, Henne-Bruns D, Beger HG, El Bayoumy K (2002) Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 15:677–685
- 49. Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El Bayoumy K (2001) Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone, via alpha-hydroxylation and carbonyl reduction pathways. Carcinogenesis 22:107–114
- 50. Melikian AA, Sun P, Prokopczyk B, El Bayoumy K, Hoffmann D, Wang X, Waggoner S (1999) Identification of benzo[a]pyrene metabolites in cervical mucus and DNA adducts in cervical tissues in humans by gas chromatography-mass spectrometry. Cancer Lett 146:127–134
- International Agency for Research on Cancer (1995) Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans, vol 64. IARC, Lyon, FR, pp 35–378
- 52. International Agency for Research on Cancer (1973) Some aromatic amines, hydrazine and related substances, *N*-nitroso compounds and miscellaneous alkylating agents. IARC monographs on the carcinogenic risk of chemicals to man, vol 4. IARC, Lyon, FR, pp 127–136
- Skipper PL, Tannenbaum SR (1990) Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis 11:507–518
- 54. Skipper PL, Peng X, SooHoo CK, Tannenbaum SR (1994) Protein adducts as biomarkers of human carcinogen exposure. Drug Metab Rev 26:111–124
- 55. Landi MT, Zocchetti C, Bernucci I, Kadlubar FF, Tannenbaum S, Skipper P, Bartsch H, Malaveille C, Shields P, Caporaso NE, Vineis P (1996) Cytochrome P450 1A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomark Prev 5:693–698
- 56. Probst-Hensch NM, Bell DA, Watson MA, Skipper PL, Tannenbaum SR, Chan KK, Ross RK, Yu MC (2000) N-Acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenylhemoglobin adduct levels. Cancer Epidemiol Biomark Prev 9:619–623
- Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC (2001) Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 93:538–545
- 58. Pryor WA, Stone K, Zang LY, Bermudez E (1998) Fractionation of aqueous cigarette tar extracts: fractions that contain the tar radical cause DNA damage. Chem Res Toxicol 11:441–448
- 59. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611–650

- 60. Jalas J, Hecht SS, Murphy SE (2005) Cytochrome P450 2A enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen. Chem Res Toxicol 18:95–110
- Nebert DW, Dalton TP, Okey AB, Gonzalez FJ (2004) Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279:23847–23850
- Armstrong RN (1997) Glutathione-S-transferases. In: Guengerich FP (ed) Comprehensive toxicology: biotransformation, vol 3. Elsevier Science, New York, pp 307–327
- Burchell B, McGurk K, Brierley CH, Clarke DJ (1997) UDPglucuronosyltransferases. In: Guengerich FP (ed) Comprehensive toxicology: biotransformation, vol 3. Elsevier Science, New York, pp 401–436
- 64. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, Dolzan V, Haugen A, Hirvonen A, Ingelman-Sundberg M, Kihara M, Kiyohara C, Kremers P, Le Marchand L, Ohshima S, Pastorelli R, Rannug A, Romkes M, Schoket B, Shields P, Strange RC, Stucker I, Sugimura H, Garte S, Gaspari L, Taioli E (2003) CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer 104:650–657
- Liu G, Zhou W, Christiani DC (2005) Molecular epidemiology of non-small cell lung cancer. Semin Respir Crit Care Med 26:265–272
- 66. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525–1530
- 67. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T (2001) Somatic activation of the K-*ras* oncogene causes early onset lung cancer in mice. Nature 410:1111–1116

- Lubet RA, Zhang Z, Wiseman RW, You M (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp Lung Res 26:581–593
- Sekido Y, Fong KW, Minna JD (1998) Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1378:F21–F59
- Bode AM, Dong Z (2005) Signal transduction pathways in cancer development and as targets for cancer prevention. Prog Nucleic Acid Res Mol Biol 79:237–297
- Hecht SS (2003) Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Rev Cancer 3:733–744
- Schuller HM (2002) Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2:455–463
- 73. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA (2003) Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111:81–90
- Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL, Cooke JP (2001) Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7:833–839
- 75. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ (2005) Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 65:664–670
- Belinsky SA (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26:1481–1487
- World Health Organization (1997) Tobacco or health: a global status report. WHO, Geneva, pp 10–48
- Blot WJ, Fraumeni JF Jr (1996) Cancers of the lung and pleura. In: Schottenfeld D, Fraumeni J (eds) Cancer epidemiology and prevention. Oxford University Press, New York, pp 637–665
- American Cancer Society (2001) Cancer facts and figures 2001. American Cancer Society, Atlanta, GA, pp 29–32